Evaluation of High Dose Rifampicin and Dialkylcarbamoyl chloride (DACC)-coated dressings to improve outcomes in Mycobacterium ulcerans disease
Phase 3
- Conditions
- Skin and Connective Tissue Diseases
- Registration Number
- PACTR202011867644311
- Lead Sponsor
- ondon School of Hygiene and Tropical Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 112
Inclusion Criteria
i.Age between 5 and 80 years old
ii.Have a nodule, plaque or ulcer, with or without associated oedema.
iii.Lesion that has tested positive for M. ulcerans by Polymerase Chain Reaction (PCR) for IS2404
iv.Participant or parent/guardian able to give informed consent.
v.Able and willing to follow the protocol requirements
Exclusion Criteria
i.Current participation in any interventional study at the time of randomisation
ii.Known allergy to any component of DACC dressing
iii.Known contraindication to either Rifampicin or clarithromycin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method